Dobrodosli na sajt Medjunarodnog centra za razvoj finansijskog trzistaDobrodosli na sajt Medjunarodnog centra za razvoj finansijskog trzista
O namaUsluge CentraProizvodi CentraSavetovanja i seminariNasi rezultatiNasi klijenti
Arhiva vesti
Gorenje u 2016. ostvarilo dobit od 8,4 mil EUR - Prihodi porasli na 1,26 mlrd EUR
Slovenački proizvođač kućnih aparata Gorenje lani je ostvario 8,43 mil EUR neto dobiti, objavio je koncern iz Velenja, čiji je gubitak u 2015. godini iznosio 8 mil EUR.

Čista dobit je za 400.000 EUR viša od prve procene u januaru, a prihodi Gorenja lani su porasli za 2,7% i iznosili su 1,26 mlrd EUR.

Gorenje je lani povećalo finansijsku stabilnost otplatom dela duga, pa je sada odnos između neto finansijskog duga i EBIDTA 3,9 prema 1, a smanjeni su i troškovi finansiranja proizvodnje.

Investicije Gorenja u razvoj proizvoda lani su iznosile 32,3 mil EUR, a ulaganja u marketinške aktivnosti 26,4 mil EUR, prenosi


Chinese Fosun Pharma also interested in acquiring Stada
The Chinese company Shanghai Fosun Pharmaceutical is planning to make a bid for the takeover of the German generic pharmaceutical company Stada, which is already the center of the battle between two consortiums.

Fosun Pharma has had preliminary negotiations with several funds, including CVC, regarding a joint takeover, but it might decide to first act alone and then bring in a financial adviser.

Following the pressure of the biggest shareholders to take into consideration the option of strategic partnership, consortiums Adventa and Permire, as well as Baina and Cinvena, showed interest in Stada. It is expected that the final bids will be known before this year"s Easter.

Analysts estimate that partnerships between funds and pharmaceutical companies make sense, since companies from this field often stand to make significant savings in the acquisition process, which then gives the funds the advantage in a potential price war over the takeover.

The same sources note that, in Stada"s case, the funds might offer up to EUR 60 per share, whereas the final bids will probably hover around the current level of EUR 58 per share, bringing the company"s value to EUR 3.6 billion, Wisebroker reports.


"Mali" akcionari
Emitenti
Posrednici
Investitori
Proizvodi Centra
Arhiva vesti
Kontaktirajte nasKnjiga gostijuMapa sajta